Tag: <span>expression systems</span>

From the Editor-in-Chief: A “Renaissance” of Sorts Within the Biologics Industry

We just completed our 6th ISBioTech Spring Meeting, and it was a resounding success. And while the attendee numbers were up considerably, the more important aspects for me were that we had the “right” people, plus incredibly valuable content. Then what impressed me the most was the happiness and hopefulness I saw during the meals, receptions, and the banquet. We’ve been organizing these meetings for over 20 years, and I haven’t experienced anything like this since our earliest days in Williamsburg…

Read MoreFrom the Editor-in-Chief: A “Renaissance” of Sorts Within the Biologics Industry

Biologics Production

aav adeno-associated virus baculovirus expression technology biologics bioproduction car t-cells chimeric antigen-receptor expression systems hpv vaccine internal reference materials mab monoclonal antibodies rhabdovirus sf9 cells therapeutic cancer vaccines vaccine development vaccines

From the Editor-in-Chief: Biomedical Research and Biopharmaceutical Advances in Cuba

European organizations have been doing business with Cuba during its last 30 years of biotechnology development, and have benefited from both licensing and distribution agreements for generic pharmaceuticals, as well as vaccines and other biologicals. However, as far as direct US/Cuban interactions, we’ll probably have to go through a period of “low-level” scientific exchanges before there is much interaction. As a starting point, it has been proposed by the American Association for the Advancement of Science (AAAS) that an official scientific and technology agreement be established to form a broader framework for interactions…

Read MoreFrom the Editor-in-Chief: Biomedical Research and Biopharmaceutical Advances in Cuba

Biologics Production

biologics bioproduction cigb cuba expression systems herber biotec mab monoclonal antibodies polyclonal antibodies therapeutic cancer vaccines tropical diseases vaccine development vaccines

Continuous Bioprocessing and Perfusion: Wider Adoption Coming as Bioprocessing Matures

Batch processing has long been the predominant bioprocessing paradigm, both up- and downstream. Bioprocessing fluids are processed incrementally, piped as a bolus or transferred via vessels from one process and piece of equipment to the next. This continues to work well, including a number of technological advances resulting in improvements that continue to make bioprocessing more efficient. Upstream and overall process yields are essentially doubling about every five years, with this largely driven by improved cell lines, expression systems and genetic engineering, culture media, and equipment. Among the technologies now gaining increasing adoption and market share for biopharmaceutical manufacture is continuous (bio) processing, with perfusion currently the leading technology, in terms of adoption. The use of incremental, one-step-at-a-time, classic batch processing in biopharmaceutical manufacture is different than most other major products manufacturing and high-tech industries, where processing is generally more continuous. In this context, the move toward more continuous processing in manufacturing is a common characteristic of industries starting to reach maturity. Continuous processing is exemplified by assembly lines, and petroleum refining with processing involving a rather continuous flow of the material being manufactured from one unit operation to the next. Continuous processing generally follows and eventually replaces incremental manufacturing…

Read MoreContinuous Bioprocessing and Perfusion: Wider Adoption Coming as Bioprocessing Matures

Biologics Production

batch processing biopharmaceuticals continuous bioprocessing continuous perfusion downstream bioprocessing expression systems genetic engineering process yields upstream processing